Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Non-Segmental Vitiligo

NCT07533019 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT07533019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07533019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, 24-Week, Multicenter, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Non-Segmental Vitiligo
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Recruiting
Start date
April 14, 2026
Completion date
September 30, 2027
Enrollment
66 (estimated)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

non-segmental vitiligo (nsv), vitiligo